CLINICAL TRIALS PROFILE FOR INVERSINE
✉ Email this page to a colleague
All Clinical Trials for Inversine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00262470 ↗ | Treatment of Orthostatic Intolerance | Active, not recruiting | National Institutes of Health (NIH) | Phase 1/Phase 2 | 1997-04-01 | This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder. |
| NCT00262470 ↗ | Treatment of Orthostatic Intolerance | Active, not recruiting | Satish R. Raj | Phase 1/Phase 2 | 1997-04-01 | This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder. |
| NCT00319319 ↗ | Nicotinic Receptor Augmentation of SSRI Antidepressants | Completed | Donaghue Medical Research Foundation | Phase 2 | 2003-01-01 | The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial. |
| NCT00319319 ↗ | Nicotinic Receptor Augmentation of SSRI Antidepressants | Completed | Yale University | Phase 2 | 2003-01-01 | The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial. |
| NCT00455650 ↗ | Study of the Effects of Mecamylamine and Varenicline in Schizophrenia | Completed | National Alliance for Research on Schizophrenia and Depression | N/A | 2007-03-01 | We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Inversine
Condition Name
Clinical Trial Locations for Inversine
Trials by Country
Clinical Trial Progress for Inversine
Clinical Trial Phase
Clinical Trial Sponsors for Inversine
Sponsor Name
